A prospective clinical utility study demonstrates that physicians use the 40-gene expression profile (40-GEP) to guide clinical management decisions for Medicare-eligible patients with cutaneous squamous cell carcinoma (cSCC)
Main Article Content
Keywords
40-gene expression profile, 40-GEP, clinical management, cutaneous squamous cell carcinoma, Medicare, clinical utility
References
2. Ibrahim, et al Future Oncol 2021
3. Borman, et al Diagn Pathol 2022
4. Teplitz, et al JDD 2019
5. Farberg, et al CMRO 2020
6. Litchman, et al CMRO 2020
7. Au, et al Dermatol Ther 2022
8. Hooper, et al Cancer Inv 2022
9. Soliman, et al BMC Cancer, 2020
10. Martin, et al Curr Med Res Opin, 2015
11. Asad, et al Am J Surg, 2008
12. Gore, et al Cancer, 2017
13. Basourakos, et al, Front. Oncol, 2021
14. Lee, et al, Chest, 2021
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.